HGCC
Human Glioma Cell Cultures.

HGCC is a biobanking effort to provide a panel of newly established and characterized GBM cell lines from GBM patient surgical samples, currently holding 48 cell lines. The HGCC cell lines and accompanying data are available as an open resource facilitating accurate modeling of GBM diversity for basic research and drug discovery.

Overview
  • Diagnosis
  • Clinical Data
  • Blood
  •  
  • Markers
  • Gene Expression
  • Genetics
  •  
  • Markers
  • Gene Expression
  • Genetics
  • In vitro properties
  • Tumor initiation
  • Mouse survival
  • Markers
  •  

HGCC Biobank

Generic placeholder image

Glioblastoma and GSCs
From patient to treatment.

The concept of glioma stem cells (GSCs) has attracted a lot of interest, and a glioma-initiating cell bearing stem cell characteristic has been proposed, with the ability to seed new tumors through the capacity to evade chemotherapy and irradiation.

Basic cancer research, including preclinical tumor models and testing of candidate drugs needs optimized in vitro models that better reflect the patient’s disease, including modeling of the cancer stem cell compartment. We have set up a biobanking effort to culture and characterize a new panel of cells, derived from GBM patient biopsies, based on a combination of two validated techniques for culturing GSCs (Xie et al. 2015). Here, we report the establishment, genomic characterization and in vivo validation of 48 patient-derived GBM cell lines cultured under stem cell conditions, and that they represent all four molecular GBM subtypes.

Patient Material

DiagnosisNumber of patientsMean age (span)MaleFemaleNumber of cell linesCell line rate (%)
All glioma10160.7 (21-82)56455447.4
Grade IV83 5355.8
Glioblastoma8262.5 (21-82)47355356.4
Gliosarcoma178100.0
Grade III13 17.7
Anaplastic astrocytoma445.8(29-63)04125
Anaplastic oligodendroglioma952.6(26-73)4500
Grade II500
Oligodendroglioma455.3(42-68)3100
Pleomorphic xanthoastrcytoma1571000

HGCC in Action
Drug Development and Characterization.

A number of studies have been published using HGCC. Here we summarize the cell lines used in each study.

U3002
U3004
U3005
U3008
U3009
U3013
U3016
U3017
U3019
U3020
U3021
U3024
U3027
U3028
U3029
U3031
U3033
U3034
U3035
U3037
U3039
U3042
U3046
U3047
U3048
U3051
U3053
U3054
U3056
U3060
U3062
U3065
U3067
U3068
U3071
U3073
U3078
U3082
U3084
U3085
U3086
U3088
U3101
U3110
U3117
U3118
U3121
U3123
Xie et. al.
Wee et. al.
Babateen et.al.
Savary et.al.
Yu et.al.
Kundu et. al.
Wee et. al.
Truve et.al.
Roy et. al.
Schmidt et. al.
Segerman et. al.
Jiang et. al.

Supported By

References

The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes.Yuan Xie*, Tobias Bergström*, Yiwen Jiang*, Patrik Johansson*, Voichita Dana Marinescu, Nanna Lindberg, Anna Segerman, Grzegorz Wicher, Mia Niklasson, Sathishkumar Baskaran, Smitha Sreedharan, Isabelle Everlien, Marianne Kastemar, Annika Hermansson, Lioudmila Elfineh, Sylwia Libard, Eric Charles Holland, Göran Hesselager, Irina Alafuzoff, Bengt Westermark*, Sven Nelander*, Karin Forsberg-Nilsson*, Lene Uhrbom*
EBioMedicine 2015
U3002, U3004, U3005, U3008, U3009, U3013, U3016, U3017, U3019, U3020, U3021, U3024, U3027, U3028, U3029, U3031, U3033, U3034, U3035, U3037, U3039, U3042, U3046, U3047, U3048, U3051, U3053, U3054, U3056, U3060, U3062, U3065, U3067, U3068, U3071, U3073, U3078, U3082, U3084, U3085, U3086, U3088, U3101, U3110, U3117, U3118, U3121, U3123
Selective calcium sensitivity in immature glioma cancer stem cells.Wee S, Niklasson M, Marinescu VD, Segerman A, Schmidt L, Hermansson A, Dirks P, Forsberg-Nilsson K, Westermark B, Uhrbom L, Linnarsson S, Nelander S, Andäng M.
PLoS One. 2014 Dec 22;9(12):e115698.
U3047, U3013, U3065, U3037, U3035, U3024, U3084, U3046, U3017
Etomidate,propofol and diazepam potentiate GABA-evoked GABAA currents in a cell line derived from human glioblastoma.Babateen O, Jin Z, Bhandage A, Korol SV, Westermark B, Forsberg Nilsson K, Uhrbom L, Smits A, Birnir B.
Eur J Pharmacol. 2014 Dec 12;748C:101-107.
U3047
Snail depletes the tumorigenic potential of glioblastoma.Savary K, Caglayan D, Caja L, Tzavlaki K, Bin Nayeem S, Bergström T, Jiang Y, Uhrbom L, Forsberg-Nilsson K, Westermark B, Heldin CH, Ferletta M, Moustakas A.
Oncogene. 2013 Mar 25.
U3028, U3034
Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures.Yu D, Jin C, Ramachandran M, Xu J,Nilsson B, Korsgren O, Le Blanc K, Uhrbom L, Forsberg-Nilsson K, Westermark B, Adamson R, Maitland N, Fan X, Essand M.
PLoS One. 2013;8(1):e54952. Epub 2013 Jan 25.
U3013, U3054
Heparanase Promotes Glioma Progression and is Inversely Correlated with Patient survival.Kundu S, Xiong A, Spyrou A, Wicher G, Marinescu VD, Edqvist PD, Zhang L, Essand M, Dimberg A, Smits A, Ilan N, Vlodavsky I, Li JP, Forsberg-Nilsson K.
Mol Cancer Res. 2016 Aug 26.
U3013, U3024
ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells.Wee B, Pietras A, Ozawa T, Bazzoli E, Podlaha O, Antczak C, Westermark B, Nelander S, Uhrbom L, Forsberg-Nilsson K, Djaballah H, Michor F, Holland EC.
Sci Rep. 2016 Jul 26;6:25956.
U3020
Utilizing the Dog Genome in the Search for Novel Candidate Genes Involved in Glioma Development-Genome Wide Association Mapping followed by Targeted Massive Parallel Sequencing Identifies a Strongly Associated Locus.Truve K, Dickinson P, Xiong A, York D, Jayashankar K, Pielberg G, Koltookian M, Muren E, Fuxelius HH, Weishaupt H, Swartling FJ, Andersson G, Hedhammar Å, Bongcam-Rudloff E, Forsberg-Nilsson K, Bannasch D, Lindblad-Toh K.
PLoS Genet. 2016 May;12(5):e1006000.
U3004, U3009, U3013, U3021, U3029, U3031, U3054
Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells.Roy A, Coum A, Marinescu VD, Polajeva J, Smits A, Nelander S, Uhrbom L, Westermark B, Forsberg-Nilsson K, Ponten F, Tchougounova E.
Oncotarget. 2015 Sep 15;6(27):23647-61.
U3016, U3047, U3117, U3065, U3060, U3062, U3101
Case-specific potentiation of glioblastoma drugs by pterostilbeneSchmidt L, Baskaran S, Johansson P, Padhan N, Matuszewski D, Green LC, Elfineh L, Wee S, Häggblad M5, Martens U, Westermark B, Forsberg-Nilsson K, Uhrbom L, Claesson-Welsh L, Andäng M, Sintorn IM, Lundgren B, Lönnstedt I, Krona C, Nelander S
Oncotarget
U3013, U3017, U3024, U3037, U3065, U3084, U3002, U3004, U3005, U3009, U3020, U3035, U3008, U3016, U3021, U3027, U3031, U3046, U3029, U3028, U3033, U3039, U3047, U3085, U3019, U3034, U3056, U3082, U3086, U3117, U3053, U3054, U3060, U3073, U3078, U3088, U3051, U3062, U3068, U3110, U3118, U3129
Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition.Segerman A, Niklasson M, Haglund C, Bergström T, Jarvius M, Xie Y, Westermark A, S#246;nmez D, Hermansson A, Kastemar M, Naimaie-Ali Z, Nyberg F, Berglund M, Sundström M, Hesselager G, Uhrbom L, Gustafsson M, Larsson R, Fryknäs M, Segerman B, Westermark B
Cell Reports
U3017, U3065, U3117, U3118, U3121, U3167
Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of OriginJiang Y, Marinescu VD, Xie Y, Jarvius M, Maturi NP, Haglund C, Olofsson S, Lindberg N, Olofsson T, Leijonmarck C, Hesselager G, Alafuzoff I, Fryknäs M, Larsson R, Nelander S, Uhrbom L
Cell Reports
U3002, U3005, U3008, U3009, U3013, U3017, U3020, U3021, U3024, U3027, U3028, U3029, U3031, U3033, U3034, U3035, U3037, U3039, U3042, U3046, U3047, U3048, U3051, U3053, U3056, U3060, U3062, U3065, U3068, U3071, U3073, U3078, U3082, U3084, U3085, U3086, U3088, U3093, U3101, U3102, U3104, U3110, U3117, U3118, U3121, U3123, U3129, U3137, U3140, U3146, U3155, U3164, U3167, U3169, U3172, U3173, U3175, U3180, U3189, U3198, U3202

Image Attributions

Glioblastoma MRI, Case courtesy of Dr Frank Gaillard, Radiopaedia.org. From the case Glioblastoma multiforme (GBM) with PNET component

Start page background: Intermediate magnification micrograph of a glioblastoma
Copyright © 2011 Nephron
Permission is granted to copy, distribute and/or modify this image under the terms of the GNU Free Documentation License Version 1.2 or any later version published by the Free Software Foundation.